New Retina Radio:

New Retina Radio Journal Club

New Retina Radio Journal Club

11.26.21

New Retina Radio Journal Club: Biosimilars in Wet AMD

The biosimilars are coming—and studies about them are starting to fill the literature. One such study is the COLUMBUS-AMD study, which evaluated the clinical equivalence of FYB201 to ranibizumab for the treatment of wet AMD. Aleksandra Rachitskaya, MD, breaks down the study with Emmanuel Chang, MD, PhD; Michael Klufas, MD; and Dmitra Skondra, MD. The group expands on what biosimilars are and asks what the future of retina could look like if biosimilars are approved for clinical use.  This editorially independent podcast is supported with advertising.

Other Podcast Episodes

07.18.25

Diabetic Retinopathy Severity and Income Status

Ben Young, MD; Phoebe Mellen, MD; and Jordan Deaner, MD

06.20.25

Photobiomodulation for Age-related Macular Degeneration

Moderator Barton Blackorby, MD; Hong-Uyen Hua, MD; and Louis Cai, MD

03.21.25

Rates of Ocular AEs After Faricimab Injection

Maura Di Nicola, MD; Sruthi Arepalli, MD; and Barton Blackorby, MD

12.19.24

Switching from Aflibercept to Faricimab in Wet AMD Patients

Ben Young, MD, MS; Lediana Goduni, MD; and Joshua Uhr, MD,

11.21.24

New Retina Radio Journal Club w/ VBS: Does Metformin Reduce AMD Risk?

Moderator Rebecca Soares, MD; Matt Starr, MD; and Nikisha Kothari, MD

09.17.24

New Retina Radio Journal Club w/ VBS: Risk of Death, Stroke, and MI After RAO

Katherine Talcott, MD; Kyle Kovacs, MD; and Phoebe Mellen, MD

Show More